{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:38:21Z","timestamp":1794591501546,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,4,15]],"date-time":"2010-04-15T00:00:00Z","timestamp":1271289600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Complement Altern Med"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1472-6882-10-13","type":"journal-article","created":{"date-parts":[[2010,4,15]],"date-time":"2010-04-15T18:14:32Z","timestamp":1271355272000},"source":"Crossref","is-referenced-by-count":172,"title":["Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)"],"prefix":"10.1186","volume":"10","author":[{"given":"Harald","family":"Matthes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krummenerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Giensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,15]]},"reference":[{"key":"290_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/bmj.333.7563.340","volume":"333","author":"P Collins","year":"2006","unstructured":"Collins P, Rhodes J: Ulcerative colitis: diagnosis and management. BMJ. 2006, 333: 340-3. 10.1136\/bmj.333.7563.340.","journal-title":"BMJ"},{"key":"290_CR2","first-page":"411","volume":"65","author":"PI Zigra","year":"2007","unstructured":"Zigra PI, Maipa VE, Alamanos YP: Probiotics and remission of ulcerative colitis: a systematic review. Neth J Med. 2007, 65: 411-8.","journal-title":"Neth J Med"},{"key":"290_CR3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/pmj.2006.047035","volume":"82","author":"M Lukas","year":"2006","unstructured":"Lukas M, Bortlik M, Maratka Z: What is the origin of ulcerative colitis? Still more questions than answers. Postgrad Med J. 2006, 82: 620-5. 10.1136\/pmj.2006.047035.","journal-title":"Postgrad Med J"},{"key":"290_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","volume":"132","author":"G D'Haens","year":"2007","unstructured":"D'Haens G, Sandborn WJ, Feagan BG: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007, 132: 763-86. 10.1053\/j.gastro.2006.12.038.","journal-title":"Gastroenterology"},{"key":"290_CR5","first-page":"845","volume":"63","author":"R Furuta","year":"2005","unstructured":"Furuta R, Kusugami K, Goto H: [Enema therapy for ulcerative colitis patients]. Nippon Rinsho. 2005, 63: 845-9.","journal-title":"Nippon Rinsho"},{"key":"290_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1440-1746.2006.04399.x","volume":"22","author":"R Furuta","year":"2007","unstructured":"Furuta R, Ando T, Watanabe O: Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis. J Gastroenterol Hepatol. 2007, 22: 261-7. 10.1111\/j.1440-1746.2006.04399.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"290_CR7","first-page":"68","volume":"2","author":"A Nissle","year":"1951","unstructured":"Nissle A: [Mutaflor and its medical significance]. Z Klin Med. 1951, 2: 68-","journal-title":"Z Klin Med"},{"key":"290_CR8","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/gut.2003.037747","volume":"53","author":"W Kruis","year":"2004","unstructured":"Kruis W, Fric P, Pokrotnieks J: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004, 53: 1617-23. 10.1136\/gut.2003.037747.","journal-title":"Gut"},{"key":"290_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/00042737-200306000-00017","volume":"15","author":"M Guslandi","year":"2003","unstructured":"Guslandi M, Giollo P, Testoni PA: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003, 15: 697-8. 10.1097\/00042737-200306000-00017.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"290_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/07315724.2003.10719276","volume":"22","author":"H Ishikawa","year":"2003","unstructured":"Ishikawa H, Akedo I, Umesaki Y: Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003, 22: 56-63.","journal-title":"J Am Coll Nutr"},{"key":"290_CR11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1046\/j.1365-2036.1999.00560.x","volume":"13","author":"A Venturi","year":"1999","unstructured":"Venturi A, Gionchetti P, Rizzello F: Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999, 13: 1103-8. 10.1046\/j.1365-2036.1999.00560.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"290_CR12","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/00365520701396091","volume":"42","author":"Y Tsuda","year":"2007","unstructured":"Tsuda Y, Yoshimatsu Y, Aoki H: Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol. 2007, 42: 1306-11. 10.1080\/00365520701396091.","journal-title":"Scand J Gastroenterol"},{"key":"290_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1196\/annals.1326.005","volume":"1072","author":"SK Bohm","year":"2006","unstructured":"Bohm SK, Kruis W: Probiotics: do they help to control intestinal inflammation?. Ann N Y Acad Sci. 2006, 1072: 339-50. 10.1196\/annals.1326.005.","journal-title":"Ann N Y Acad Sci"},{"key":"290_CR14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s11894-007-0055-7","volume":"9","author":"EM Quigley","year":"2007","unstructured":"Quigley EM: Probiotics in the management of colonic disorders. Curr Gastroenterol Rep. 2007, 9: 434-40. 10.1007\/s11894-007-0055-7.","journal-title":"Curr Gastroenterol Rep"},{"key":"290_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/mnfr.200700147","volume":"52","author":"P Seksik","year":"2008","unstructured":"Seksik P, Dray X, Sokol H: Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?. Mol Nutr Food Res. 2008, 52: 906-12. 10.1002\/mnfr.200700147.","journal-title":"Mol Nutr Food Res"},{"key":"290_CR16","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/mnfr.200700139","volume":"52","author":"H Steed","year":"2008","unstructured":"Steed H, Macfarlane GT, Macfarlane S: Prebiotics, synbiotics and inflammatory bowel disease. Mol Nutr Food Res. 2008, 52: 898-905. 10.1002\/mnfr.200700139.","journal-title":"Mol Nutr Food Res"},{"key":"290_CR17","first-page":"30","volume":"148","author":"S Bohm","year":"2006","unstructured":"Bohm S, Kruis W: Neue Mirkoorganismen bringen Ruhe in den Darm [Probiotics in chronic inflammatory bowel disease]. MMW Fortschr Med. 2006, 148: 30-4.","journal-title":"MMW Fortschr Med"},{"key":"290_CR18","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1128\/JCM.02600-05","volume":"44","author":"H Sokol","year":"2006","unstructured":"Sokol H, Lepage P, Seksik P: Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. J Clin Microbiol. 2006, 44: 3172-7. 10.1128\/JCM.02600-05.","journal-title":"J Clin Microbiol"},{"key":"290_CR19","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/0016-5085(87)90621-4","volume":"92","author":"LR Sutherland","year":"1987","unstructured":"Sutherland LR, Martin F, Greer S: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987, 92: 1894-8.","journal-title":"Gastroenterology"},{"key":"290_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ibd.3780040202","volume":"4","author":"SB Hanauer","year":"1998","unstructured":"Hanauer SB: Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis. 1998, 4: 79-83. 10.1002\/ibd.3780040202.","journal-title":"Inflamm Bowel Dis"},{"key":"290_CR21","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/gut.2004.056358","volume":"54","author":"PD Higgins","year":"2005","unstructured":"Higgins PD, Schwartz M, Mapili J: Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005, 54: 782-8. 10.1136\/gut.2004.056358.","journal-title":"Gut"},{"key":"290_CR22","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1136\/bmj.1.4979.1315","volume":"1","author":"SC Truelove","year":"1956","unstructured":"Truelove SC, Richards WC: Biopsy studies in ulcerative colitis. Br Med J. 1956, 1: 1315-8. 10.1136\/bmj.1.4979.1315.","journal-title":"Br Med J"},{"key":"290_CR23","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.3748\/wjg.v12.i38.6115","volume":"12","author":"AA van Bodegraven","year":"2006","unstructured":"van Bodegraven AA, Mulder CJ: Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?. World J Gastroenterol. 2006, 12: 6115-23.","journal-title":"World J Gastroenterol"},{"issue":"Suppl 3","key":"290_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2036.2006.03063.x","volume":"24","author":"EF Stange","year":"2006","unstructured":"Stange EF: Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease. Aliment Pharmacol Ther. 2006, 24 (Suppl 3): 64-7. 10.1111\/j.1365-2036.2006.03063.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"290_CR25","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1007\/s10620-006-9586-2","volume":"52","author":"N Uslu","year":"2007","unstructured":"Uslu N, Demir H, Saltik-Temizel IN: Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease. Dig Dis Sci. 2007, 52: 2926-9. 10.1007\/s10620-006-9586-2.","journal-title":"Dig Dis Sci"},{"key":"290_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000064461","volume":"92","author":"NE Frandsen","year":"2002","unstructured":"Frandsen NE, Saugmann S, Marcussen N: Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron. 2002, 92: 200-2. 10.1159\/000064461.","journal-title":"Nephron"},{"key":"290_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(98)06343-0","volume":"354","author":"BJ Rembacken","year":"1999","unstructured":"Rembacken BJ, Snelling AM, Hawkey PM: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999, 354: 635-9. 10.1016\/S0140-6736(98)06343-0.","journal-title":"Lancet"},{"key":"290_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1046\/j.1365-2036.1997.00225.x","volume":"11","author":"W Kruis","year":"1997","unstructured":"Kruis W, Schutz E, Fric P: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997, 11: 853-8. 10.1046\/j.1365-2036.1997.00225.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"290_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0923-2508(02)00007-4","volume":"154","author":"G Blum-Oehler","year":"2003","unstructured":"Blum-Oehler G, Oswald S, Eiteljorge K: Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res Microbiol. 2003, 154: 59-66. 10.1016\/S0923-2508(02)00007-4.","journal-title":"Res Microbiol"},{"key":"290_CR30","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1128\/JB.186.16.5432-5441.2004","volume":"186","author":"L Grozdanov","year":"2004","unstructured":"Grozdanov L, Raasch C, Schulze J: Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol. 2004, 186: 5432-41. 10.1128\/JB.186.16.5432-5441.2004.","journal-title":"J Bacteriol"},{"key":"290_CR31","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.1128\/IAI.72.10.5750-5758.2004","volume":"72","author":"J Wehkamp","year":"2004","unstructured":"Wehkamp J, Harder J, Wehkamp K: NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun. 2004, 72: 5750-8. 10.1128\/IAI.72.10.5750-5758.2004.","journal-title":"Infect Immun"},{"key":"290_CR32","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1128\/IAI.01563-06","volume":"75","author":"M Schlee","year":"2007","unstructured":"Schlee M, Wehkamp J, Altenhoefer A: Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun. 2007, 75: 2399-407. 10.1128\/IAI.01563-06.","journal-title":"Infect Immun"},{"key":"290_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1572-0241.2005.40641.x","volume":"100","author":"PD Higgins","year":"2005","unstructured":"Higgins PD, Schwartz M, Mapili J: Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?. Am J Gastroenterol. 2005, 100: 355-61. 10.1111\/j.1572-0241.2005.40641.x.","journal-title":"Am J Gastroenterol"}],"container-title":["BMC Complementary and Alternative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6882-10-13\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6882-10-13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6882-10-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6882-10-13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T07:03:41Z","timestamp":1548227021000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/1472-6882-10-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,15]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["290"],"URL":"https:\/\/doi.org\/10.1186\/1472-6882-10-13","relation":{},"ISSN":["1472-6882"],"issn-type":[{"value":"1472-6882","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,15]]},"article-number":"13"}}